Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.
- Conditions
- locally advanced pancreatic cancerpancreatic neoplasmFOLFIRINOXstereotactic radiotherapy
- Registration Number
- NL-OMON27030
- Lead Sponsor
- Foundation for Liver and Gastrointestinal Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 51
Inclusion Criteria
Cytological or histologically confirmation of pancreatic cancer.
-WHO performance status of 0 or 1
Exclusion Criteria
-Prior radiotherapy, chemotherapy or resection (bypass surgery allowed).
-Lymph node metastases from primary tumor outside the field of radiation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - overall survival
- Secondary Outcome Measures
Name Time Method - number of toxicity events related to chemotherapy<br /><br>- radiological response after chemotherapy and radiotherapy<br /><br>- number of resections at end of stereotactic radiotherapy<br /><br>- time to locoregional disease progression<br /><br>- time to development of distant metastases<br /><br>- predictive value of a set of biological markers for treatment response (miRNAs)